AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$HNGE

Pursley James sold $479K of HNGE

Pursley James (President) sold 8,995 shares of Hinge Health, Inc. (HNGE) at $53.29 ($0.48M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pursley James
Published May 27, 2026, 11:14 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HNGE
Neutral
medium confidence
Mentioned
$HNGE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGENeutralLow
01

Why it matters

This disclosure updates insider activity records but does not provide evidence of a new business development, financial result, or regulatory event. The most plausible effect is a small sentiment/positioning adjustment rather than a fundamental repricing.

02

Market read

HNGE insider selling is disclosed, but the 10b5-1 designation suggests scheduled trading with limited informational content.

03

What to watch

Traders may overreact to headline insider selling; the key nuance is the plan being pre-arranged, which often correlates with scheduled execution rather than new information.

Relevance 6/10Timing: Same-day/next-session positioning possible as traders digest the Form 4, but no new operating catalyst is present.

Background

The article is an SEC EDGAR Form 4 insider transaction: President Pursley James sold HNGE shares on 2026-05-26; the sale is marked as open-market and executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$HNGENeutralMedium confidence
Context

Hinge Health (HNGE) disclosed an officer open-market sale of 8,995 shares ($479,367.84) under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited immediate impact; any reaction should be small unless accompanied by other fundamental news.

Evidence & confidence

The filing is an SEC Form 4 for an officer sale, explicitly tied to a pre-arranged 10b5-1 plan, which reduces interpretive weight versus unscheduled sales.

Market effects

Sector

Minimal—this is company-specific insider liquidity/plan activity, not a sector-wide signal.

Regional

None indicated; filing is US-based and not tied to regional demand or regulation changes.

Global

None indicated; no international transaction or guidance change mentioned.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine diversification/liquidity rather than bearish expectations.

Key entities

  • issuer
    Hinge Health, Inc.

    Subject of the Form 4 insider transaction; officer sale of 8,995 shares for ~$479.4K under a 10b5-1 plan.

  • insider
    Pursley James

    President who executed the open-market sale disclosed in the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HNGE insider trading history →

Related articles

AUG 28
$HNGEHighAI 8/10

Could Hinge Health (HNGE) Stock Win as Digital Healthcare Expands Beyond MSK Care?

Hinge Health (NYSE:HNGE) raised its 2026 revenue guidance to $856M-$860M, up from $822.16M consensus. Q2 2026 revenue grew 53% YoY to $213M, with non-GAAP operating income doubling to $62M. The company announced a $105M acquisition of Cylinder Health and expanded its share repurchase program by $300M. Analysts RBC and Truist raised price targets to $110 and $112, respectively, citing strong growth and platform expansion.

finance.yahoo.com3 min
AUG 19
$HNGEMedAI 8/10

HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?

Hinge Health (HNGE) stock has risen 90% YTD, outperforming industry and S&P 500. Q2 revenue grew 53% YoY to $213M, with 2026 guidance raised to $856-$860M. AI and automation improved margins, while new care programs expand market reach. Analysts project 2026 EPS of $2.50 and 2027 EPS of $3.29. Growth is driven by member yield, AI efficiency, and new care offerings, but execution risks remain.

zacks.com3 min
AUG 15
$HNGEMed

Jim Cramer says one stock hitting new highs is still a screaming buy

Jim Cramer reiterated a triple buy call on Hinge Health (HNGE) on “Mad Money” Aug. 11. The stock hit a new all-time high of $93.13 on Aug. 10 and is up about 85.83% YTD, per Yahoo Finance. Hinge reported Q2 2026 revenue of $213 million (+53% YoY), free cash flow of $99.6 million, and raised FY guidance to $856-$860 million. It also agreed to a $105 million cash acquisition (Cylinder Health) to expand into GI care.

yahoo.com6 min
AUG 12
$HNGEMed

Hinge Health (HNGE) Just Bought Its Way Into A New Market, So Now What?

Hinge Health (NASDAQ:HNGE) reported Q2 revenue of $213 million, up 53% year over year, above guidance of $200 million to $202 million. Gross margin rose to 87% and operating income to $62 million. The company said it used $105 million cash to acquire Cylinder Health for gastrointestinal care, while also expanding its migraine offering. It raised FY revenue guidance to $856 million to $860 million and authorized a $300 million buyback.

insidermonkey.com7 min
AUG 5
$HNGEHighAI 9/10

Why is Hinge Health stock surging today?

Hinge Health (HNGE) shares rose 11.6% after the company reported Q2 2026 revenue of $212.8M (+53% YoY) and non-GAAP diluted EPS of $0.59 vs $0.13 consensus. Free cash flow exceeded $100M. Hinge raised FY2026 revenue guidance to $818M-$824M and Q3 guidance to $223M-$225M, and agreed to buy Cylinder Health for $105M cash. Analysts lifted price targets.

investing.com4 min